Journal of Shandong University (Health Sciences) ›› 2018, Vol. 56 ›› Issue (10): 9-17.doi: 10.6040/j.issn.1671-7554.0.2018.1020
Previous Articles Next Articles
CLC Number:
| [1] 支修益,石远凯,于金明.中国原发性肺癌诊疗规范(2015版)[J].中华肿瘤杂志,2015,37(1): 67-78. [2] Ando S, Suzuki M, Yamamoto N, et al. The prognostic value of both neuron-specific enolase(NSE)and Cyfra21-1 in small cell lung cancer [J]. Anticancer Res, 2004, 24(3b): 1941-1946. [3] Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003[J]. J Clin Oncol, 2004, 22(2): 330-353. [4] Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer [J]. Oncology, 2001, 61(S1): 3-13. [5] Petra S, Rudolf H, Stefan H, et al. National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Lung Cancer[J]. Tumor Biology, 2006. [6] 中华医学会检验分会,卫生部临床检验中心,中华检验医学杂志编辑委员会. 肿瘤标志物的临床应用建议[J].中华检验医学杂志, 2012, 35(2): 103-116. [7] 王兰兰,许化溪.临床免疫学检验[M].5版.北京:人民卫生出版社,2013. [8] Paone G, De Angelis G, Munno R, et al. Discriminant analysis on small-cell lung cancer and non-small-cell lung cancer by means of NSE and CYFRA 21-1[J]. Eur Respir J,1995, 8(7): 1136-1140. [9] Ebert W, Muley T. CYFRA 21-1 in the follow-up of inoperable non-small-cell lung cancer patients treated with chemotherapy[J]. Anticancer Res, 1999, 19(4A): 2669-2672. [10] Takei Y, Minato K, Tsuchiya S, et al. CYFRA21-1: an indicator of survival and therapeutic effect in lung cancer[J]. Oncology, 1997, 54(1): 43-47. [11] 中国合格评定国家认可委员会. CNAS-CL02:2012 医学实验室质量和能力认可准则[EB/OL]. https://www.cnas.org.cn/rkgf/sysrk/jbzz/2013/12/750592.shtml, 2013-12-11/2018-09-03. [12] 中国合格评定国家认可委员会. CNAS-CL38:2012 医学实验室质量和能力认可准则在临床化学检验领域的应用说明[EB/OL]. https://www.cnas.org.cn/rkgf/sysrk/rkyyzz/2014/05/782592.shtml, 2014-05-06/2018-09-03. [13] 李金明,刘辉.临床免疫学检验技术[M].北京:人民卫生出版社,2015. [14] 唐古生,沈茜.临床免疫检测的干扰因素和解决办法[A].中华医学会,中华医学会第七次全国中青年检验医学学术会议论文汇编[C] , 2012: 33-34. [15] 中国医师协会肿瘤医师分会,中国抗癌协会肿瘤临床化疗专业委员会.中国表皮生长因子受体基因敏感性突变和间变淋巴瘤激酶融合基因阳性非小细胞肺癌诊断治疗指南(2015版)[J]. 中华肿瘤杂志, 2015, 37(10): 796-799. [16] 中华人民共和国国家卫生和计划生育委员会. 药物代谢酶和药物作用靶点基因检测技术指南(试行)和肿瘤个体化治疗检测技术指南(试行)[EB/OL]. 国卫医医护便函〔2015〕240号,http://www.moh.gov.cn/yzygj/s3593/201507/fca7d0216fed429cac797cdafa2ba466.shtml, 2015-07-31/2018-09-03. [17] 中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家组.中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家共识(2016版)[J].中华病理学杂志, 2016, 45(4): 217-220. [18] 中国专家共识专家组.非小细胞肺癌血液EGFR基因突变检测中国专家共识[J].中华医学杂志, 2015, 95(46): 3721-3726. [19] Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology[J]. Arch Pathol Lab Med, 2013, 137(6): 828-860. [20] Thomas A, Liu SV, Subramaniam DS, et al. Refining the treatment of NSCLC according to histological and molecular subtypes[J]. Nat Rev Clin Oncol, 2015, 12(9): 511-526. [21] Cheng L, Alexander RE, Maclennan GT, et al. Molecular pathology of lung cancer: key to personalized medicine[J]. Mod Pathol, 2012, 25(3): 347-369. [22] Piotrowska Z, Sequist LV. Epidermal growth factor receptor-mutant lung cancer: new drugs, new resistance mechanisms, and future treatment options[J]. Cancer J, 2015, 21(5): 371-377. [23] Zhang K, Yuan Q. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer[J]. J Cancer Res Ther, 2016, 12(Supplement): C131-C137. [24] Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance[J]. Cancer Discov, 2017, 7(2): 137-155. [25] Zhang J, Park D, Shin DM, et al. Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities[J]. Acta Biochim Biophys Sin(Shanghai), 2016, 48(1): 11-16. [26] 王恩华,朱明华,步宏,等.非小细胞肺癌靶向药物治疗相关基因检测的规范建议[J].中华病理学杂志, 2016, 45(2): 73-77. [27] Zhang S, Xia B, Jiang H, et al. Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology[J]. Oncotarget, 2016, 7(31): 50477-50489. [28] Wang W, Song Z, Zhang Y. A comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance[J]. Cancer Med, 2017, 6(1): 154-162. [29] Malapelle U, Pisapia P, Rocco D, et al. Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients[J]. Transl Lung Cancer Res, 2016, 5(5): 505-510. [30] Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA[J]. Nat Rev Cancer, 2017, 17(4): 223-238. [31] Normanno N, Denis MG, Thress KS, et al. Guide to detecting epidermal growth factor receptor(EGFR)mutations in ctDNA of patients with advanced non-small-cell lung cancer[J]. Oncotarget, 2017, 8(7): 12501-12516. |
| [1] | LI Bo-Bo, LI Dao-Tang, LIU Shu-Guang, WANG Xing-Wu. Expression of serum DKK-1 in esophageal cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 58-61. |
| [2] | HUANG Peiwen, WANG Xudong. A new drug for non-small cell lung cancer: Telisotuzumab Vedotin, an antibody-drug conjugate targeting c-Met protein [J]. Journal of Shandong University (Health Sciences), 2026, 64(3): 124-130. |
| [3] | Intelligent Orthopedics Subgroup of Chinese Association of Orthopedic, Subgroup for Prevention and Control of Spinal and Spinal Cord Injury Diseases of Professional Committee for Prevention and Control of Spinal Diseases of Chinese Preventive Medicine Association. Expert consensus on measurement sites and annotation of artificial intelligence-based spinal degenerative imaging(2025) [J]. Journal of Shandong University (Health Sciences), 2026, 64(2): 1-10. |
| [4] | Intelligent Orthopedics Subgroup of Chinese Association of Orthopedic, Subgroup for Prevention and Control of Spinal and Spinal Cord Injury Diseases of Professional Committee for Prevention and Control of Spinal Diseases of Chinese Preventive Medicine Association. Expert consensus on robot-assisted transforaminal lumbar interbody fusion surgical techniques [J]. Journal of Shandong University (Health Sciences), 2026, 64(2): 11-21. |
| [5] | ZHU Yongcai, XIE Yan, QI Qiuchen, LI Peilong, WANG Chuanxin, DU Lutao. Value of a combined model based on ATM gene methylation of peripheral blood mononuclear cells in the early diagnosis of pancreatic cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 78-88. |
| [6] | ZHAO Hanqing, ZHOU Xinrui, LI Zijian, TANG Xing. Application of circulating tumor cells combined with serological detection in non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 79-85. |
| [7] | DU Xue, LI Chunxia, LIU Yunxia, ZHANG Tao. Dynamic prediction model for the colorectal cancer patients prognosis based on MFPC-Cox [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 101-110. |
| [8] | XU Nianxing, WEI Dong, QIAO Junjie, ZHAN Bingyan. Predictive value of CD8+, IL-6, and PaO2 for immunotherapy-triggered radiation recall pneumonitis in unresectable stage ⅢB/C and IV non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(2): 29-35. |
| [9] | Thoracoscopic Committee of Shandong Provincial Endoscopic Surgery Quality Control Center. Shandong Provincial expert consensus on control indexes of VATS/RATS perioperative quality for non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(12): 1-5. |
| [10] | LI Yiyuan, MA Shan, LI Aihua, LONG Fei. EBUS-guided iodine-125 seed implantation for the treatment of central lymph node metastases in lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(12): 26-34. |
| [11] | LIU Zhenkun, LYU Jiling, XU Weiwei, MA Litian, ZHANG Caiqing. Value of tNGS testing and conventional culture for BALF in the diagnosis of NSCLC complicated with IPFD [J]. Journal of Shandong University (Health Sciences), 2025, 63(11): 36-45. |
| [12] | . Shandong Province expert consensus on multidisciplinary treatment of breast cancer(2024 edition) [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 10-16. |
| [13] | Orthopaedic Rehabilitation Special Committee of Chinese Speaking Orthopaedic Society. Expert consensus on accelerated recovery of knee function after total knee arthroplasty [J]. Journal of Shandong University (Health Sciences), 2024, 62(10): 48-61. |
| [14] | WANG Yanan, LIANG Chuanjie, JIA Mengqi, YUAN Huiqing. Role of protein disulfide isomerase TMX1 in promoting chemotherapy resistance in lung cancer [J]. Journal of Shandong University (Health Sciences), 2023, 61(8): 31-39. |
| [15] | ZHONG Lu, XUE Fuzhong. A Lung cancer risk prediction model based on Bayesian network uncertainty inference [J]. Journal of Shandong University (Health Sciences), 2023, 61(4): 86-94. |
|
||
